Inflammatory Bowel Diseases Flashcards

1
Q

two major disorders of IBD

A
Ulcerative colitis (UC)
Chrones disease (CD)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

chronic inflammatory condition

A

CD and UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

relapsing and remitting episodes of inflammation

A

UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

inflammation limited to the mucosal layer of the colon

A

UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

transmural inflammation and what does it lead to

A

CD > fibrosis and obstructive clinical picture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

involves rectum and colon preferably

A

UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

favors illeum but can go anywhere in GI tract

A

CD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

may extend proximally and continuously to involve more of the colon

A

UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

skip lesions or cobble stone apearance

A

CD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

age diagnosed for UC and CD

A

15-40 and 50-80

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

male predominance

A

UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

female predominance

A

CD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

racial predominance for both

A

jewish, caucasian

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

percentage of CD and UC patients that have a 1st degree relative with IBD

A

10-25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

smoking is not a risk factor

A

UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

smoking is a risk factor

A

CD (cessation resulting in less flares)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

3 main factors of IBD

A

genetic predisposition
altered dysregulation of immune response (helper T cells)
altered response to gut bacteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

clinical manifestations of UC

A
diarrhea +/- blood
frequent and small BM
colicky periumbilical > LLQ abd pain
bowel urgency
tenesmus
incontinence
mucus from rectum
when rectum is involved, constipation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

onset of symptoms in UC

A

gradual and progressive over a few weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

severity of UC

A

10 stools daily with severe cramps and bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

how does physical exam help diagnosis of UC

A

it really doesnt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what causes UC?

A

inflammation of mucosa leading to ulceration, edema, bleeding, and fluid/electrolyte loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what immune reaction is prompted

A

cytokines are released by macrophages and target Type2 helper T cells causing them to be cytotoxic to surrounding tissues > inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

microscopic level of UC

A

acute and chonic inflammatory changes to mucosa (lamina propria)
villous atrophy
discharge of mucus from goblet cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

signs of systemic toxicity

A

fever >99.5
tachy >90
anemia <10.5
elevated ESR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

acute complications of UC

A

severe bleeding
fulminant colitis
toxic megacolon
perforation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

fulminant colitis

A

> 10 stools per day with continuous bleeding
abd pain and distension
toxic symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

toxic megacolon

A

colonic diameter >6cm or >9 with toxicity
potentially deadly
can perforate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

how many patients develop extraintestinal manifestations?

A

only 10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

when do extraintestinal manifestations most commonly occur>

A

following an episode of colitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

extraintestinal manifestations of UC

A

arthritis of large joints
uveitis
cholangitis (fibrosis of gallbladder)
unprovoked PE or DVT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

when do you start a workup for UC

A

chronic diarrhea >4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

what labs to order for UC

A

ESR: inflammation
CBC: WBC and hemoglobin
PANCA and ASCA: pANCA+ > UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

stool studies for UC, what to look out for

A
salmonella
shigella
campylobacter
c.diff
ova/parasites
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

why is it important to take a good history for UC

A

rule out anal STDs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

is imagine required to diagnose UC

A

no

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

imaging done to diagnose UC

A

endoscopy + biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

findings on endoscopy that indicate UC

A

bowel wall thickening
vascular markings due to engorgement of mucosa
edema, exudates, friability
pseudopolyps (more extensive UC)
erosions and ulcerations
continuous and circumfrential beginning at the anal verge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

how likely is relapse in UC?

A

70% within the first 10 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

predictors of frequent relapse

A

disease flare within 2 years of diagnosis
presence of fever or weight loss upon diagnosis
active disease in preceding year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

how likely is it for UC to extend up the colon?

A

20% of pts in the first 5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

what does repeated inflammation prompt in UC

A

benign strictures only in 10% of patients
rectosigmoid colon
evaluate on endoscopy and biopsy to rule out cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

is there increased risk for cancer with UC?

A

yes, colorectal cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

greatest risk factors for colorectal cancer and UC?

A

extent of colitis (how much of the GI tract)

duration of the disease (how long they’ve been diagnosed)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

highest risk for colorectal cancer of UC patients

A

pancolitis

46
Q

when does the risk start for colorectal cancer?

A

8-10 years after pancolitis diagnosis

47
Q

step 1 therapy for proctitis or proctosigmoiditis

A

5-ASA
Mesalanine (Canasa) BID topical for rectal (suppository)
Mesalanine (Rowasa) BID topical for >colon (enema)

48
Q

with topical therapy how soon will relief and bleeding subside in UC?

A

a few days

49
Q

how long must UC pts stay on topical mesalanine for complete healing

A

6-8weeks –> gradual taper

50
Q

step 2 therapy for UC

A

5-ASA topical + oral if they don’t respond

or if they refuse topical

51
Q

5-ASA PO drugs

A

Sulfalazine (azulfidine)

mesalanine (asacol, lialda,pentasa, apriso)

52
Q

sulfalazine mechanism

A

prodrug splits into sulfapyridine and mesalanine by bacteria in the colon

53
Q

MOA of sulfasalazine

A

blocks prostaglandin production in the colon and inhibits inflammations

54
Q

S.E. of sulfasalazine

A

due to sulfapyridine component
nausea, headache, rash, fever
leukopenia in first 3 months + fever and rash
inhibits folic acid transport across cell membrane
watery diarrhea, abd pain, pancreatitis

55
Q

monitoring while on 5-ASA therapy for UC

A

baseline CBC and LFTS
continue q2w x3m
qmonth x3m
q3m after

56
Q

what do you need to prescribe with sulfasalazine

A

1mg Folic acid qd

57
Q

when don’t we recommend maintenance 5-ASA therapy

A

patient with first episode of mild ulcerative proctatitis that responds to treatment

58
Q

when do we recommend maintence therapy for UC

A

pts with >1 relapse per year

ALL patients with proctosigmoiditis

59
Q

when can we consider taking a pt off maintenance therapy for UC

A

when they’ve been on meds for 2+ years and get clearance from GI specialist

60
Q

pts on topical therapy for induction of remission

A

1 5-ASA suppository QHS with proctiits
1 5-ASA enema QHS with proctosigmoiditis
possible they need sulfasalazine to remain in remission

61
Q

first line therapy for left sided colitis or pancolitis

A

combo of oral and topical 5-ASA (enema)

62
Q

second line therapy for left sided colitis or pancolitis

A

no remission in 2-4 weeks or systemic symptoms
GLUCOCORTICOIDS (prednisone)
only for pts with systemic symptoms, toxicosis, tachycardic

63
Q

which patients with left colitis or pancolitis need maintenance therapy?

A

all of them
can taper down from BID enemas to QHS
no glucocorticoids, taper after pt stable for 2-4 weeks

64
Q

when can we use supportive treatment for UC?

A

in those with MILD disease and without SYSTEMIC TOXICITY

65
Q

diarrhea support in UC

A

loperamide (immodium)

66
Q

abdominal cramping support in UC

A

anticholinergic medicines like

hyoscamine (Levsin)

67
Q

avoid what med while treating UC

A

NSAIDs

opiates

68
Q

surgical treatment for UC

A

total colectomy

69
Q

when are total colectomies most commonly done in UC

A

intractable disease
dependence upon steroids to maintain remission
progression of dx with worsening symptoms
major complications with medications

70
Q

when to conduct colorectal screenings in UC

A

after 8 years in pancolitis
after 15 years in left colitis
repeat every 1-2 years regardless of reults

71
Q

when to perform osteoporosis screening in UC pts

A
all UC patients who are
postmenopausal
>60 y.o
ongoing corticosteroid use >3m
history of low-trauma fractures
72
Q

where does chrones occur?

A
anywhere in the the GI tract
80% most commonly in the distal ileum
50% in the ileum and colon
20% in colon
5-10% in mouth, esophagus, or duodenum
73
Q

what do the cytokines target in CD?

A

type 1 helper T cells

just like UC, cytotoxic effect on surrounding tissues > villous atrophy

74
Q

why does diarrhea occur in CD?

A

excessive fluid secretion bc of inflammed bowel, but atrophy doesn’t allow the bowel to reabsorb

bile salts aren’t absorbed by terminal ileum

75
Q

describe abd pain in CD

A

crampy
periumbilical > RLQ
transmural involvement
relieved with BM

76
Q

diarrhea in CD

A

common at presentation
NOT usually bloody
may include mucus or pus

77
Q

how does CD in only the colon present?

A

just like UC

78
Q

evidence of malabsorption in CD

A

weight loss, anorexia, NV

79
Q

complication of deepening transmural involvement in CD

A

fistula formation in bladder, skin, bowel, and vagina

increasing chances longer diagnosed

80
Q

if a sinus tract does not extend all the way to another organ in CD it forms an…

A

abscess

81
Q

extraintestinal manifestations of CD

A

same as UC (more frequent if colonic involvement of a flare)

82
Q

labs for diagnosis

A

ESR: inflammation
Iron: deficiency due to bleeding or poor absorption of Fe
B12: ileum absorption
CBC: hemoglobin, white count
pANCA and ASCA: + ASCA > CD
(if colon involed, pANCA might be positive

83
Q

stool studies look out

A

same as UC

84
Q

endoscopic findings

A

aphthous ulcers
cobblestoning
linear ulcers
discontinuous lesions

85
Q

CD disease course

A

remission followed by exacerbation

active disease in past year > 70% chance having disease active 1 year later

86
Q

patients who go in remission for 1 year

A

80% chance of remaining in remission another year

only 13% of CD pts

87
Q

pts who have annual relapses

A

20%

88
Q

pts who go in and out of remission?

A

70%

89
Q

predictors of more severe disease cours

A
>40y.o @ diagnosis
perianal or rectal disease
smoking
low education level
initial requirements of glucocorticoids
90
Q

choice of treatment for CD depends on

A

anatomic location of disease
severity
goal of therapy

91
Q

treatment for oral lesion

A

triamcinolone oral gel

92
Q

first line therapy for Ileitis and colitis with CD

A

glucocorticoids (prednisone) + immunomodulators or biological agents

93
Q

glucocorticoids in CD

A

60-80% respondance in 10-14 days
taper drug after condition improves
not long term

94
Q

support in CD for diarrhea

A

immodium (loperamide)

95
Q

immunomodulators

A

Azathioprine (imuran)

Methotrexate (CHEAPER!!!)

96
Q

azathioprine (imuran) MOA

A

inhibits an enzyme needed for DNA synthesis

affects proliferating cells especially T and B cells

97
Q

how long does it take for Azathioprine to be effective

A

3-6 months

98
Q

role of azathioprine

A

to get people into remission who have symptoms even on chronic steroid therapy

99
Q

risks of azathioprine

A

secondary infection
malignancy
leukopenia (long term)
thrombocytopenia (long term)

100
Q

methotrexate mOA

A

interferes with DNA synthesis, repair, cellular replication
rapidly dividing cells are more sensitive to this effect (malignant cells, bone marrow, fetal cells, intestinal mucosa, bladder cells)

101
Q

role of methotrexate

A

induction and maintenance of CD remission

102
Q

risk of methotrexate

A

teratogenic
males should not try to get pregnant until 3 months after stopping medication
females should not try to get pregnant until they have one full ovulatory cycle after stopping medication

103
Q

unexpected severe symptoms of methotrexate

A

bone marrow suppression, aplastic anemia (WITH NSAIDs)

104
Q

biological agents, when do we use them?

A

Inflizimab (remicade)

when you fail prednisone + methotrexate

105
Q

how is inflizimab given?

A

IV

106
Q

MOA of infliximab

A

antibody against TNF > blocks it in the serum and cell surface causing lysis of macrophages and T cells

107
Q

role of infliximab

A

induction of remission (if it works stay on it for maintenace)

108
Q

risks of infliximab

A

increased risk of opportunisitc infections
test for TB prior to prescribing
higher rates of Hodgkin’s and non-Hodgkin’s lymphoma in those who started therapy <18 y.o occuring 1-84 months post start of therapy (most prescribed concomitant immunosuppressants)
Heart Failure: do not use with pts with moderate to severe heart failure

109
Q

who needs surgery for CD?

A

intracable symptoms
obstruction
perforation

110
Q

colorectal screening for CD?

A

same as UC